How does Tyr-hGH 177-191 differ from HGH Fragment 176-191?

Both center on the lipolytic C-terminal region of growth hormone; Tyr-hGH 177-191 adds an N-terminal tyrosine primarily to allow labeling and tracing in research while keeping the fat-mobilizing core sequence.

Why does the fragment avoid growth hormone's metabolic downsides?

The C-terminal fragment separates lipolytic activity from the full hormone's IGF-1 induction and insulin-antagonizing effects, so it is studied for fat mobilization without those broader actions.

← All peptides

Weight & Metabolic

Research Chemical

Tyr-hGH 177-191

Also known as: Tyr-hGH 177-191, Tyrosine HGH Fragment

Tyr-hGH 177-191 is a tyrosine-extended analog of the C-terminal lipolytic fragment of human growth hormone. The added tyrosine residue is used mainly to enable labeling and tracing while the fragment retains the fat-mobilizing activity associated with the 176-191 region.

Mechanism of Action

The growth hormone 177-191 sequence corresponds to the C-terminal region of hGH that carries the hormone's lipolytic activity without its growth-promoting or insulin-antagonizing effects. This fragment is thought to act on beta-3 adrenergic-linked pathways in adipose tissue, stimulating hormone-sensitive lipase and promoting triglyceride breakdown and fatty-acid release while sparing IGF-1 induction. The N-terminal tyrosine addition in the Tyr-hGH analog provides a residue for radioiodination or other labeling so the fragment can be tracked in binding and distribution studies, while preserving the core fat-mobilizing behavior.

Half-life: Short, on the order of roughly 20-40 minutes consistent with small hGH fragments
Administration Routes: subcutaneous
Research Status: Research Chemical